NCT06181292View on ClinicalTrials.gov

Safety and Immunogenicity of a Booster Vaccination with an Adapted Vaccine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

913

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

June 17, 2024

Study Completion Date

June 17, 2024

Conditions
SARS-CoV2 Infection
Interventions
BIOLOGICAL

PHH-1V81

booster of PHH-1V81

BIOLOGICAL

Comirnaty Omicron XBB1.5

booster of Comirnaty Omicron XBB1.5

Trial Locations (10)

17001

Hospital Josep Trueta, Girona

28050

Hospital HM Sanchinarro, Madrid

28223

Hospital Quironsalud Madrid, Madrid

28938

Hospital HM Puerta del Sur, Móstoles

29010

Hospital Regional de Málaga, Málaga

46010

Hospital Clínico Universitario de Valencia, Valencia

48903

Hospital de Cruces, Barakaldo

08916

Hospital Germans Trias i Pujol, Badalona

08023

Hospital HM Delfos, Barcelona

08540

CAP Centelles, Centelles

Sponsors
All Listed Sponsors
lead

Hipra Scientific, S.L.U

INDUSTRY

NCT06181292 - Safety and Immunogenicity of a Booster Vaccination with an Adapted Vaccine | Biotech Hunter | Biotech Hunter